BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Reduces Position in DENTSPLY SIRONA Inc. (XRAY)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp trimmed its position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 4.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 108,712 shares of the medical instruments supplier’s stock after selling 5,002 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in DENTSPLY SIRONA were worth $6,502,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Commonwealth Bank of Australia grew its holdings in DENTSPLY SIRONA by 19.0% in the 2nd quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 260 shares in the last quarter. Acrospire Investment Management LLC purchased a new stake in DENTSPLY SIRONA in the 2nd quarter valued at $113,000. Dupont Capital Management Corp purchased a new stake in DENTSPLY SIRONA in the 2nd quarter valued at $116,000. Massey Quick Simon & CO. LLC purchased a new stake in DENTSPLY SIRONA in the 3rd quarter valued at $124,000. Finally, Korea Investment CORP grew its holdings in DENTSPLY SIRONA by 139.9% in the 2nd quarter. Korea Investment CORP now owns 2,145 shares of the medical instruments supplier’s stock valued at $139,000 after buying an additional 1,251 shares in the last quarter. Hedge funds and other institutional investors own 96.58% of the company’s stock.

In other news, insider Mark Thierer bought 77,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were purchased at an average price of $66.04 per share, with a total value of $5,085,080.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Francis J. Lunger sold 8,900 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $65.90, for a total value of $586,510.00. The disclosure for this sale can be found here. 1.99% of the stock is currently owned by corporate insiders.

DENTSPLY SIRONA Inc. (XRAY) opened at $64.99 on Wednesday. The firm has a market capitalization of $14,906.42, a price-to-earnings ratio of 25.86, a PEG ratio of 2.57 and a beta of 1.31. The company has a current ratio of 2.32, a quick ratio of 1.59 and a debt-to-equity ratio of 0.21. DENTSPLY SIRONA Inc. has a twelve month low of $52.53 and a twelve month high of $68.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $978.99 million. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The company’s revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.66 EPS. research analysts predict that DENTSPLY SIRONA Inc. will post 2.65 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 12th. Investors of record on Friday, December 29th will be paid a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 0.54%. DENTSPLY SIRONA’s payout ratio is -10.09%.

Several analysts have issued reports on XRAY shares. Zacks Investment Research cut DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a report on Monday, October 30th. HC Wainwright restated a “buy” rating and issued a $68.00 target price on shares of DENTSPLY SIRONA in a report on Monday, November 6th. Morgan Stanley reiterated an “overweight” rating and set a $69.00 price target (up from $67.00) on shares of DENTSPLY SIRONA in a report on Friday, October 6th. TheStreet upgraded DENTSPLY SIRONA from a “c” rating to a “b-” rating in a report on Friday, November 3rd. Finally, BidaskClub cut DENTSPLY SIRONA from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 16th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $68.83.

COPYRIGHT VIOLATION NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://ledgergazette.com/2017/12/13/british-columbia-investment-management-corp-reduces-position-in-dentsply-sirona-inc-xray.html.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply